Sandy Robbins

Before joining MMS, Sandy accumulated over 18 years of experience in the CRO industry, holding various Commercial and Finance leadership roles. Her background includes expertise in developing pricing models, supervising proposal and contract workflows, optimizing CRM data structures, and crafting management reports and dashboards. Sandy’s goal is to ensure that MMS has the right processes, systems, and personnel in place to support its ongoing commercial growth and expansion.

Sandy’s educational credentials include an MBA in Finance from the University of Chicago Booth School of Business, along with a bachelor’s degree in chemical engineering from the University of Illinois at Urbana-Champaign. She also holds certifications in Six Sigma and Digital Health, further exemplifying her broad skillset and commitment to professional development.

Suggested For You

perspectives

March 6th, 2025

Overview of FDA Guidance for Industry on Assessment of Ovarian Toxicity in Premenopausal Adults During Development for Oncologic Products

webinar

March 25th, 2025

Overcoming NDA/BLA Submission Challenges: Practical Strategies for Success

perspectives

February 13th, 2025

Helping European Drug Development Companies Succeed in the US Market

news

February 12th, 2025

MMS Acquires Exploristics and KerusCloud Simulation Platform to Expand Biostatistics and Data Science Capabilities as a Global Data-Focused CRO

perspectives

January 30th, 2025

Post-PDUFA VII Updates: FDA Meetings Public Workshop & Lessons Learned

perspectives

January 21st, 2025

REMS Modifications and Revisions: A Retrospective from the Past 12 Months

regulatory intelligence

January 17th, 2025

The FDA’s AI Guidance and its Seven Steps into the Future of Drug Development

regulatory intelligence

January 17th, 2025

New FDA Protocol Deviation Guidance:  Planning for the Things That Don’t Go According to Plan

perspectives

January 9th, 2025

How to Create Efficiencies When Creating Simultaneous NDA and MAA Submissions for the FDA and EMA

perspectives

January 2nd, 2025

Informed Consent in Clinical Research: Understanding its Significance and Sponsor Obligations

perspectives

December 17th, 2024

Oncology Drug Development: Webinar Learnings on the Use of Expedited Pathways and Oncology Center of Excellence Programs

perspectives

December 11th, 2024

Why Emerging Biotech Companies are Increasingly Turning to Specialized Data CROs